1. Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. 2006; Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst. 98:599–609. DOI:
10.1093/jnci/djj158. PMID:
16670385.
Article
2. Castelo M, Hu SY, Dossa F, Acuna SA, Scheer AS. 2020; Comparing observation, axillary radiotherapy, and completion axillary lymph node dissection for management of axilla in breast cancer in patients with positive sentinel nodes: a systematic review. Ann Surg Oncol. 27:2664–76. DOI:
10.1245/s10434-020-08225-y. PMID:
32020394.
Article
3. Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. 2017; Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 318:918–26. DOI:
10.1001/jama.2017.11470. PMID:
28898379. PMCID:
PMC5672806.
Article
4. Elmore LC, Appleton CM, Zhou G, Margenthaler JA. 2013; Axillary ultrasound in patients with clinically node-negative breast cancer: which features are predictive of disease? J Surg Res. 184:234–40. DOI:
10.1016/j.jss.2013.03.068. PMID:
23664535.
Article
6. Youn HJ, Ahn HR, Kang SY, Jung SH. 2020; Ultrasonography for Staging axillary lymph node in breast cancer patients. J Surg Ultrasound. 7:1–6. DOI:
10.46268/jsu.2020.7.1.1.
Article
7. Choi YJ, Ko EY, Han BK, Shin JH, Kang SS, Hahn SY. 2009; High-resolution ultrasonographic features of axillary lymph node metastasis in patients with breast cancer. Breast. 18:119–22. DOI:
10.1016/j.breast.2009.02.004. PMID:
19297159.
Article
8. Farrell TP, Adams NC, Stenson M, Carroll PA, Griffin M, Connolly EM, et al. 2015; The Z0011 trial: is this the end of axillary ultrasound in the pre-operative assessment of breast cancer patients? Eur Radiol. 25:2682–7. DOI:
10.1007/s00330-015-3683-6. PMID:
25740803.
Article
9. Angarita S, Ye L, Rünger D, Hadaya J, Baker JL, Dawson N, et al. 2021; Assessingthe burden of nodal disease for breast cancer patients with clinically positive nodes: hope for more limited axillary surgery. Ann Surg Oncol. 28:2609–18. DOI:
10.1245/s10434-020-09228-5. PMID:
33084993.
Article
10. Lim GH, Upadhyaya VS, Acosta HA, Lim JMA, Allen JC Jr, Leong LCH. 2018; Preoperative predictors of high and low axillary nodal burden in Z0011 eligible breast cancer patients with a positive lymph node needle biopsy result. Eur J Surg Oncol. 44:945–50. DOI:
10.1016/j.ejso.2018.04.003. PMID:
29705286.
Article
11. Ahn SK, Kim MK, Kim J, Lee E, Yoo TK, Lee HB, et al. 2017; Can we skip intraoperative evaluation of sentinel lymph nodes? Nomogram predicting involvement of three or more axillary lymph nodes before breast cancer surgery. Cancer Res Treat. 49:1088–96. DOI:
10.4143/crt.2016.473. PMID:
28161935. PMCID:
PMC5654155.
Article
12. Gentilini O, Veronesi U. 2012; Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node vs Observation after axillary UltraSouND). Breast. 21:678–81. DOI:
10.1016/j.breast.2012.06.013. PMID:
22835916.
13. Pilewskie M, Jochelson M, Gooch JC, Patil S, Stempel M, Morrow M. 2016; Is preoperative axillary imaging beneficial in identifying clinically node-negative patients requiring axillary lymph node dissection? J Am Coll Surg. 222:138–45. DOI:
10.1016/j.jamcollsurg.2015.11.013. PMID:
26711795. PMCID:
PMC4729648.
Article
14. Puri S, Sharma N, Newcombe RG, Kaushik M, Al-Attar M, Pascaline S, et al. 2018; Axillary tumour burden in women with one abnormal node on ultrasound compared to women with multiple abnormal nodes. Clin Radiol. 73:391–5. DOI:
10.1016/j.crad.2017.12.014. PMID:
29352595.
Article
15. Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al. 2013; Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 310:1455–61. DOI:
10.1001/jama.2013.278932. PMID:
24101169. PMCID:
PMC4075763.
Article
16. Pilewskie M, Zabor EC, Mamtani A, Barrio AV, Stempel M, Morrow M. 2017; The optimal treatment plan to avoid axillary lymph node dissection in early-stage breast cancer patients differs by surgical strategy and tumor subtype. Ann Surg Oncol. 24:3527–33. DOI:
10.1245/s10434-017-6016-y. PMID:
28762114. PMCID:
PMC5697709.
Article
17. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. 2013; Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 24:2278–84. DOI:
10.1093/annonc/mdt182. PMID:
23704196.
Article
18. van der Noordaa MEM, van Duijnhoven FH, Straver ME, Groen EJ, Stokkel M, Loo CE, et al. 2018; Major reduction in axillary lymph node dissections after neoadjuvant systemic therapy for node-positive breast cancer by combining PET/CT and the MARI procedure. Ann Surg Oncol. 25:1512–20. DOI:
10.1245/s10434-018-6404-y. PMID:
29511992.
Article
19. Kim WH, Kim HJ, Jung JH, Park HY, Lee J, Kim WW, et al. 2018; Ultrasound-guided restaging and localization of axillary lymph nodes after neoadjuvant chemotherapy for guidance of axillary surgery in breast cancer patients: experience with activated charcoal. Ann Surg Oncol. 25:494–500. DOI:
10.1245/s10434-017-6250-3. PMID:
29134374.
Article
20. Kim WH, Kim HJ, Kim SH, Jung JH, Park HY, Lee J, et al. 2019; Ultrasound-guided dual-localization for axillary nodes before and after neoadjuvant chemotherapy with clip and activated charcoal in breast cancer patients: a feasibility study. BMC Cancer. 859. DOI:
10.1186/s12885-019-6095-1. PMID:
31470821. PMCID:
PMC6716853.
Article